Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.

Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, Hartl TA, Sanders J, Conley N, Ge X, Langan M, Ramaswamy V, Ellis L, Litzenburger U, Bolin S, Theruvath J, Nitta R, Qi L, Li XN, Li G, Taylor MD, Wechsler-Reya RJ, Pinna LA, Cho YJ, Fuller MT, Elias JE, Scott MP.

Sci Signal. 2018 Sep 11;11(547). pii: eaau5147. doi: 10.1126/scisignal.aau5147.

PMID:
30206138
2.

Proteomic profiling of high risk medulloblastoma reveals functional biology.

Staal JA, Lau LS, Zhang H, Ingram WJ, Hallahan AR, Northcott PA, Pfister SM, Wechsler-Reya RJ, Rusert JM, Taylor MD, Cho YJ, Packer RJ, Brown KJ, Rood BR.

Oncotarget. 2015 Jun 10;6(16):14584-95.

3.

SnapShot: Medulloblastoma.

Rusert JM, Wu X, Eberhart CG, Taylor MD, Wechsler-Reya RJ.

Cancer Cell. 2014 Dec 8;26(6):940-940.e1. doi: 10.1016/j.ccell.2014.11.015.

4.

ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.

Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao KH, Morris SR, Goldstein LS, Marra MA, Frazer KA, Jamieson CH.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6. doi: 10.1073/pnas.1213021110. Epub 2012 Dec 28.

Supplemental Content

Loading ...
Support Center